A Prospective Multicenter Sample Collection Study Using Non-invasive Methods to Investigate Mutation Burden in Non-lesional Facial Skin of Patients With a Hx of Skin Cancer
NCT ID: NCT05602337
Last Updated: 2022-11-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
180 participants
OBSERVATIONAL
2022-11-15
2025-03-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Melanoma Detection by Oblique-Incidence Optical Spectroscopy
NCT00526032
In Vivo Confocal Microscopy of Cutaneous Neoplasms and Normal Skin
NCT00588315
Study of Tumor Tissue Samples From Patients With Stage I, Stage II, or Stage III Malignant Melanoma
NCT00991991
Reflectance Confocal Microscopy of Wounds During Moh's Surgery: Feasibility Testing of a Mosaicing Algorithm for Intraoperative Imaging of Cancer Margins
NCT01872130
Sample Collection Study in Patients With Suspected Melanoma Utilizing DermTech's Non-invasive Adhesive Patch Biopsy Kits
NCT04550000
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Approximately 20-30 participants will be enrolled in each of six (6) main groups outlined below for a total of 120-180 subjects and controls:
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Immunocompetent BCC Subjects
BCC-predominant group
Observational Study Only
Non-invasive Skin Sampling
Immunocompetent SCC Subjects
SCC-predominant group
Observational Study Only
Non-invasive Skin Sampling
Immunocompetent MM Subjects
Melanoma group
Observational Study Only
Non-invasive Skin Sampling
Control
age, sex and Fitzpatrick phototype match
Observational Study Only
Non-invasive Skin Sampling
Solid Organ Transplantation Recipient - SC
At least 5 skin cancers and at least 5 years post-transplant
Observational Study Only
Non-invasive Skin Sampling
Solid Organ Transplantation Recipient
No more than 1 skin cancer and at least 5 years post-transplant
Observational Study Only
Non-invasive Skin Sampling
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Observational Study Only
Non-invasive Skin Sampling
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Is at least 18 years of age;
2. Is willing to consent to non-invasive adhesive tape sampling and DNA mutation burden analysis;
3. Has a history of 10 or more basal cell carcinomas (BCCs) and at least a 10:1 ratio of BCC to other skin cancer types; or
4. Has a history of 5 or more squamous cell carcinomas (SCCs) and at least a 5:1 ratio of SCC to other skin cancer types; or
5. Has a history of 3 or more melanomas; or
For the immunocompetent controls:
6. Has no history of skin cancer but is an age, birth sex, and Fitzpatrick phototype match (control) for an enrolled participant.
For the SOTR groups, a subject will be eligible if he or she:
7. Is age 50-70;
8. Received a heart, lung, kidney, or liver transplant at least 5 years prior to study enrollment; or
9. Has a history of 5 or more keratinocyte carcinomas (BCC or SCC), or a history of 3 or more melanomas following organ transplantation.
For the SOTR controls:
10. Is a transplant recipient age 50-70 with no more than 2 keratinocyte carcinomas.
Exclusion Criteria
2. Has undergone field therapy for actinic keratoses (e.g. 5-fluorouracil) involving the skin to be sampled within the past 12 months;
3. Has a generalized skin disorder not related to skin cancer such as psoriasis, photosensitivity disorder, or eczematous dermatitis affecting the skin to be sampled;
4. Has a known allergy to latex rubber or tape adhesives;
5. Is currently participating in another investigational study, or has participated in another study within 30 days of initiating the current study;
6. Has applied a sunscreen, moisturizer, or other topical to the skin to be sampled that cannot be adequately removed and may therefore compromise sample collection;
7. Has clinical findings which the Investigator determines may put the subject at undue risk or may interfere with the study;
8. Has undergone phototherapy or used a tanning bed within 3 months of beginning the study;
9. Has used systemic retinoids, chemotherapeutics, or immunotherapy within 3 months of beginning the study;
10. Has used an immunosuppressive medication within 3 months of study initiation, such as azathioprine, cyclosporine, methotrexate, or any of the immunosuppressive biological therapies (TNF-inhibitors, etc.);
11. Is known or suspected to have a cancer predisposition syndrome (CPS), such as Gorlin syndrome / basal cell nevus syndrome, Xeroderma pigmentosum, Ferguson-Smith syndrome, Oculocutaneous albinism, Epidermolysis bullosa, Epidermodysplasia verruciformis, Fanconi anemia, Rombo syndrome, Bazex-Dupre-Christol syndrome, Bloom syndrome, Werner syndrome, Dyskeratosis congenita, Hereditary Breast and Ovarian Cancer (HBOC) syndrome, Lynch syndrome, etc.;
12. Is known or suspected to harbor a pathogenic germline mutation within one or more cancer predisposition genes, such as TP53, CDKN2A, NF1, BAP1, DICER1, FH, SDHD, VHL, etc.; and
13. Has a history of skin cancer that cannot be verified.
18 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Pittsburgh
OTHER
DermTech
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
James Rock
Role: STUDY_DIRECTOR
DermTech
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UPMC
Pittsburgh, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DermTech 2022
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.